Jerome Benedict Durso - 06 Mar 2026 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role: President and CEO, Director
Signature: /s/ Gregory Weaver, as Attorney-in-Fact
Issuer symbol: ALT
Transactions as of: 06 Mar 2026
Net transactions value: +$70,790
Form type: 4
Filing time: 09 Mar 2026, 07:00:05 UTC
Previous filing: 22 Dec 2025
Next filing: 01 Apr 2026
SEC: View on sec.gov

Quoteable Key Fact

"Jerome Benedict Durso filed Form 4 for Altimmune, Inc. (ALT) on 09 Mar 2026."

Quick Takeaways

This page summarizes Jerome Benedict Durso's Form 4 filing for Altimmune, Inc. (ALT).
1 reported transaction and 0 derivative rows are listed below.
Filing timestamp: 09 Mar 2026, 07:00.

What Changed

Previous filing in this sequence was filed on 22 Dec 2025.
Current net transaction value: +$70,790.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Durso Jerome Benedict	President and CEO, Director	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG	/s/ Gregory Weaver, as Attorney-in-Fact	09 Mar 2026	0001698665

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALT	Common Stock, par value $0.0001	Purchase	$70,790	+20,000	+160%	$3.54	32,500	06 Mar 2026	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.5300 to $3.5500, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.5300 to $3.5500, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.